GLP-1 Weight Loss Drugs Will Disrupt the Market, $133 Billion Change

PwC's recently released report, "The Weight Loss Industry: How Weight Loss Drugs Will Disrupt the Consumer Sector," points out that the food and beverage industry will face significant impacts from GLP-1 weight loss drugs. The report is based on a survey of 3,000 American adults and reveals potential significant changes in the quantity of food purchased and consumed, dietary content, and eating frequency among consumers using or planning to use GLP-1 drugs.

GLP-1 drugs, such as Mounjaro, Ozempic, Wegovy, Cagrisema, and Rybelsus, help people lose weight by decreasing food intake and sending satiety signals to the brain, thus reducing appetite and cravings. The effectiveness of these drugs in weight loss has attracted widespread consumer attention, and PwC expects an explosive growth in the GLP-1 market. Currently, over 8% of Americans are already taking GLP-1 drugs, while nearly 35% express interest in such weight loss medications. Data from the CDC indicates that more than 100 million American adults are obese, and an analysis published in the Journal of the American Medical Association estimates that 137 million Americans may qualify for GLP-1 drug semaglutide.

PwC estimates that the current GLP-1 drug market size is approximately $133 billion, and it predicts that this could grow to $150 billion by 2030. The report emphasizes that as federal policy plans to expand the use of these anti-obesity drugs through Medicare and Medicaid and reduce costs, the user base could increase by 7 million. Therefore, businesses need to rethink their operations and revenue sources to provide value that meets new consumer demands.

Market research suggests that GLP-1 drugs may affect consumer spending on food and beverages, particularly in areas like sweets, sugary snacks, and beverages. PwC's survey found that GLP-1 users reduced their average spending on most foods by about 11%, with the largest reduction in sweet and salty snacks and baked goods. 47% of GLP-1 users reported that they now eat less, and 56% stated that they now choose healthier foods.

With the adoption of GLP-1 drugs, stakeholders in the food and beverage industry may face key impacts, including decreased foot traffic, reduced demand for processed snacks, and smaller portion sizes. Additionally, GLP-1 users may reduce their alcohol intake, potentially leading to declines in alcohol sales.

PwC suggests that food retailers, suppliers, manufacturers, and restaurant/catering operators can mitigate the impacts of GLP-1 drugs through a range of strategies. These strategies include offering low-calorie, nutrient-rich menu options, collaborating with health organizations to certify these healthier menu choices, and rethinking the combination of products with nutrition-focused recommendations, digital tools, and planning services.

Finally, PwC notes that as consumers become more health-conscious, CPG companies may need to reformulate their products, particularly targeting GLP-1 users who are moving away from traditional flavor preferences. Companies that can maintain stable prices and attract a continuously changing consumer demographic and preferences may benefit. Clearly communicating the nutritional value and health benefits of dietary choices will become increasingly important.